Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.32 USD
+0.01 (0.76%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.32 USD
+0.01 (0.76%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Zacks News
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
What's in Store for Verastem (VSTM) This Earnings Season?
by Zacks Equity Research
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
4 Healthcare Stocks Thriving on Venture Capital Funding
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.